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Objectives:  To  present  current  evidence  on  the  etiology,  risk  factors,  diagnosis,  and  manage-
ment of  early  and  late  neonatal  sepsis.
Source  of  data:  Non-systematic  review  of  the  Medline  (PubMed),  Scopus,  Web  of  Science,
Cochrane,  and  Google  Scholar  databases  regarding  the  following  terms:  neonatal  sepsis,  early
neonatal  sepsis,  late  neonatal  sepsis,  empirical  antibiotic  therapy,  sepsis  calculator,  van-
comycin, newborn,  preterm  newborn.
Data synthesis:  Neonatal  sepsis  is  a  frequent  cause  of  neonatal  morbidity  and  mortality.  Its
diagnosis is  difficult.  Continuous  observation  of  the  patient  is  critical  to  diagnostic  suspicion.
When neonatal  sepsis  is  suspected,  bacteriological  tests  should  be  collected.  Vancomycin  should
not be  routinely  using  in  the  empirical  antibiotic  regimen  in  late  neonatal  sepsis,  and  the  main
protective mechanisms  against  neonatal  sepsis  are  handwashing  and  the  use  of  breast  milk.
Conclusions:  Newborns  constitute  a  group  that  is  more  vulnerable  to  sepsis.  Knowledge  of  risk
factors and  etiological  agents  allows  a  better  approach  to  the  newborn  with  sepsis.
© 2019  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open









Estreptococo  grupo  B
Objetivos:  Apresentar  evidências  atuais  na  etiologia,  fatores  de  risco,  diagnóstico  e  manejo  da
sepse neonatal  precoce  e  tardia.
Fontes  de  dados:  Revisão  não  sistemática  feita  nas  bases  de  dados  Medline  (PubMed),  Sco-
pus, Web  of  Science,  Cochrane,  Google  Scholar  sobre  os  temas  sepse  neonatal,  sepse  neonatal
precoce, sepse  neonatal  tardia,  antibioticoterapia  empírica,  sepsis  calculator,  vancomicina,
recém-nascido,  recém-nascido  pré-termo.
 Please cite this article as: Procianoy RS, Silveira RC. The challenges of neonatal sepsis management. J Pediatr (Rio J). 2020;96(S1):80--6.
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icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Síntese  de  dados:  A  sepse  neonatal  é  uma  causa  frequente  de  morbimortalidade  neonatal.  O
seu diagnóstico  é  difícil.  A  observação  contínua  do  paciente  é  fundamental  para  uma  suspeição
diagnóstica.  Ao  se  suspeitar  de  sepse  neonatal  devem-se  coletar  exames  bacteriológicos.  Não
usar, rotineiramente,  vancomicina  no  esquema  empírico  de  antibiótico  na  sepse  neonatal  tardia.
Os principais  mecanismos  protetores  da  sepse  neonatal  são  a  lavagem  de  mãos  e  o  uso  do  leite
materno.
Conclusões:  Os  recém-nascidos  constituem  um  grupo  mais  vulnerável  à  sepse.  O  conhecimento
dos fatores  de  risco  e  dos  agentes  etiológicos  permite  uma  melhor  abordagem  do  recém-nascido
séptico.
© 2019  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este é  um  artigo


























Neonatal  sepsis  is  a  clinical  syndrome  with  hemodynamic
changes  and  other  systemic  clinical  manifestations  resulting
from  the  presence  of  pathogenic  microorganisms  (bacteria,
viruses,  or  fungi)  in  normally  sterile  fluid,  such  as  blood  or
cerebrospinal  fluid  (CSF)  in  the  first  month  of  life.1 Neonatal
sepsis  is  an  important  cause  of  neurocognitive  sequelae  and
neonatal  mortality.2,3
Neonatal  sepsis  is  classified  according  to  the  time  of  onset
as  early  or  late.  In  general,  early  neonatal  sepsis  is  consid-
ered  when  the  clinical  condition  appears  within  the  first  72  h
of  life.  The  exception  to  this  definition  is  neonatal  sepsis
caused  by  Streptococcus  agalactiae, which,  although  having
a  perinatal  etiology,  can  occur  within  the  first  7  days  of  life.
Late  neonatal  sepsis  is  that  which  starts  after  72  h  of  life.1
For  the  purposes  of  this  article,  early  neonatal  sepsis  will  be
considered  as  starting  within  the  first  72  h  of  life  and  late
neonatal  sepsis  after  72  h  of  life.
The  etiological  agents  of  early  and  late  neonatal  sepsis
are  quite  distinct.
Early  neonatal  sepsis  is  acquired  in  the  peripartum
period,  before  or  during  childbirth;  therefore,  the  microor-
ganisms  are  usually  from  the  maternal  genitourinary  tract.
According  to  data  from  the  American  Neonatology  Network,
Gram-positive  microorganisms  are  the  etiological  agents  in
62  %  of  early  neonatal  sepsis  cases,  and  in  43  %  of  the  total,
the  identified  microorganism  is  Streptococcus  agalactiae.
Gram-negative  microorganismscomprise  37  %  of  the  etio-
logical  agents  of  early  neonatal  sepsis,  of  which  29  %  are
Escherichia  coli.4
Late  neonatal  sepsis  occurs  most  often  in  infants  who
remain  hospitalized  for  long  periods,  such  as  preterm  or
full-term  infants  who  require  prolonged  hospitalization  and
invasive  procedures,  with  the  most  common  microorgan-
isms  being  those  acquired  in  the  hospital  setting.  According
to  the  American  Neonatology  Network,  in  79  %  of  the
situations  the  identified  microorganisms  are  Gram-positive,
with  coagulase-negative  Staphylococcus  occurring  in  57  %
of  the  total  and  Staphylococcus  aureus  in  12  %.  Gram-
negative  microorganisms  constitute  19  %  of  the  total,  with
Escherichia  coli  being  the  most  frequently  identified  among
them,  accounting  for  7  %  of  the  total.  Fungi  are  found  in  6




razilian  Neonatal  Research  Network  show  results  that  are
imilar  to  the  American  findings  regarding  the  etiological
gents  of  late  neonatal  sepsis.6
Eventually,  late  sepsis  can  manifest  in  newborns  in  the
ut-of-hospital  setting;  the  most  common  microorganisms
re  those  of  community  origin,  such  as  Staphylococcus
ureus  and  Escherichia  coli.
Neonatal  sepsis  can  also  have  a  viral  etiology;  however,
he  present  review  focuses  on  discussing  bacterial  neonatal
epsis.
arly neonatalsepsis
he  incidence  of  early  sepsis  in  the  United  States  is  around
.77  cases  per  1000  live  births,  and  when  considering  only
ewborns  above  34  weeks  of  gestational  age,  it  is  around  0.5
ases  per  1000  live  births.7,8 Since  intrapartum  antibiotic
herapy  was  implemented  for  pregnant  women  colonized
ith  Streptococcus  agalactiae, the  incidence  of  early  neona-
al  sepsis  has  fallen  sharply  in  the  United  States,  and  in
ervices  that  screen  and  prevent  perinatal  streptococci
nfection.
The  risk  factors  for  early  sepsis  that  have  been  pointed
ut  are:
 Streptococcus  agalactiae  colonization:  A  pregnant  woman
colonized  with  Streptococcus  agalactiae  who  has  not
undergone  intrapartum  prophylaxis  has  a  25-foldhigher
probability  of  having  a  newbornwith  early  neonatal  sepsis
than  a  non-colonized  mother.9
 Amniotic  membrane  rupture  for  more  than  18  h:  newborns
from  mothers  with  amniotic  membrane  rupture  for  more
than  18  h  are  four  times  more  likely  to  have  an  infection
than  those  born  to  mothers  without  rupture.10
 Chorioamnionitis:  the  presence  of  chorioamnionitis
increases  the  possibility  of  early  neonatal  infection.11
iagnosishe  clinical  manifestations  vary  considerably  and  are  non-
pecific,  which  makes  the  diagnosis  of  early  neonatal  sepsis































































































regimen  is  recommended:  crystalline  penicillin:  5000,000
intravenous  units  as  a  loading  dose  and  2,500,0002  
The  clinical  signs  are  from  different  systems  and  can  be
rouped  as  follows:  a)  apnea,  difficulty  breathing,  cyanosis;
)  tachycardia  or  bradycardia,  poor  perfusion  or  shock;
)  irritability,  lethargy,  hypotonia,  seizures;  d)  abdominal
istension,  vomiting,  food  intolerance,  gastric  residue,  hep-
tomegaly;  e)  unexplained  jaundice;  f)  body  temperature
nstability;  g)  petechiae  or  purpura.  To  take  into  account
he  clinical  signs,  ideally  the  newborn  should  show  mani-
estations  in  three  distinct  systems,  or  two  clinical  signs  in
istinct  systems  associated  with  a  maternal  risk  factor.12
The  Kaiser  Permanente  Northern  California  group,  which
ncompasses  14  hospitals  with  obstetric  and  neonatal  care,
as  concerned  about  the  over-requesting  of  tests  to  rule
ut  neonatal  sepsis  and  the  overuse  of  antibiotics  for  sus-
ected  early  neonatal  sepsis,  and  thus  created  a  calculator
or  newborns  with  a  gestational  age  of  34  weeks  or  over,
hich  takes  into  account  gestational  age,  time  of  ruptured
mniotic  membrane,  maternal  body  temperature,  presence
r  absence  of  Streptococcus  agalactiae  colonization,  and  use
r  non-use  of  antibiotics  in  the  period  immediately  prior
o  delivery  to  determine  the  likelihood  of  a  newborn  hav-
ng  early  neonatal  sepsis.  Considering  the  importance  of
ome  clinical  signs,  especially  those  of  respiratory  origin,
he  calculator  has  been  improved  by  including  the  newborn’s
linical  signs  in  the  first  24  h  of  life.13,14 This  calculator  is
vailable  free  of  charge  Early-Onset  Sepsis  (EOS  calculator
or  both  iPhone  and  Android).
Studies  using  retrospective  or  prospective  data  were
arried  out  to  assess  the  usefulness  and  accuracy  of  the  cal-
ulator.  Applying  the  calculator  has  been  shown  to  decrease
ntibiotic  use  in  late  preterm  or  full-term  preterm  infants
y  approximately  40  %,  without  increasing  the  risk  of  false
egative  results.8,15--17
Another  strategy  that  has  been  used  in  an  attempt  to
educe  the  use  of  antibiotics  and  over-requesting  of  labora-
ory  tests  is  to  take  into  account  the  careful  and  frequent
bservation  of  clinical  signs  in  newborns  at  risk  of  early
eonatal  sepsis.  A  European  study  that  closely  observed  clin-
cal  signs  showed  a  decrease  in  antibiotic  use  and  decreased
ospital  length  of  stay.18 In  a  recent  publication,  the  Amer-
can  Academy  of  Pediatrics  suggests  that  close  clinical
bservation  within  the  first  48  h  may  be  more  effective  than
he  EOS  calculator  in  determining  late  preterm  and  full-term
ewborns  with  early  neonatal  sepsis.19
For  newborns  with  a  gestational  age  of  34  weeks  or  less,
he  most  important  risk  factor  is  the  presence  of  chorioam-
ionitis,  defined  by  maternal  hyperthermia  equal  to  or
reater  than  39 ◦C,  or  between  38 ◦C  and  39 ◦C  accompa-
ied  by  at  least  one  of  the  following  clinical  signs:  maternal
eukocytosis,  purulent  vaginal  discharge,  or  fetal  tachycar-
ia.
The  risk  of  early  sepsis  is  high  when  preterm  birth  occurs
fter  spontaneous  labor,  when  there  is  prolonged  rupture  of
he  amniotic  membrane,  or  in  the  presence  of  chorioam-
ionitis.  The  most  adequate  approach  in  these  situations  is
o  collect  blood  culture,  cerebrospinal  fluid,  and  comple-
entary  exams,  and  to  start  empirical  antibiotic  therapy.
he  risk  of  early  sepsis  is  low  when  the  delivery  is  by  cae-
arean  section,  without  ruptured  amniotic  membrane  and
ithout  labor;  for  instance,  in  patients  with  pre-eclampsia
ho  need  to  have  their  pregnancy  interrupted  for  obstetric
easons.20Procianoy  RS,  Silveira  RC
aboratory tests
f  early  neonatal  sepsis  is  suspected,  blood  culture  and  CSF
amples  should  be  collected.  Urinalysis  is  not  indicated,
ince  urinary  infection  in  early  neonatal  sepsis  is  unusual.
Complete  blood  count  (CBC)  and  serum  C-reactive  pro-
ein  have  a  better  negative  predictive  value  than  a  positive
redictive  value.  The  most  common  CBC  findings  are  imma-
ure  to  total  neutrophil  ratio  (I/T  ratio)  >0.2,  leukopenia
below  5000),  or  leukocytosis  (>25,000).  Serial  low  C-
eactive  protein  levels  (serum  levels  below  10  mg/L)  help
o  rule  out  the  diagnosis  of  neonatal  sepsis  in  a  newborn
ith  negative  blood  culture.1
ntibiotic therapy
he  empirical  antibiotic  treatment  protocol  in  our  Unit
s  ampicillin  and  gentamicin.  This  antibiotic  regimen  cov-
rs  the  microorganisms  that  most  commonly  cause  early
eonatal  sepsis.  The  ampicillin  spectrum  is  adequate  for
treptococcus  agalactiae  and  for  Listeria,  which  occurs
ery  rarely  in  Brazil.  Gentamicin  has  an  adequate  spec-
rum  for  Gram-negative  microorganisms  and  especially  for
scherichia  coli. After  obtaining  blood  culture  results  with
he  antibiogram  test,  the  antibiotic  regimen  should  be
stablished  with  the  specific  drug  indicated  by  the  results.
In  case  of  meningitis,  with  Streptococcus  agalactiae
eing  the  etiological  agent,  it  is  recommended  to  adjust
mpicillin  to  the  appropriate  dose  indicated  for  the  treat-
ent  of  meningitis.  If  the  microorganism  is  unknown  or  in
he  case  of  a  Gram-negative  microorganism,  changing  the
ntibiotic  to  cefepime  is  indicated.
revention  of  early  neonatal  sepsis  caused  by
treptococcus agalactiae
riefly,  the  CDC  recommends  the  following  for  the  preven-
ion  of  sepsis  caused  by  Streptococcus  agalactiae21:
 Universal  screening  (for  all  pregnant  women)  of  strepto-
coccal  colonization  between  35  and  37  weeks  of  gestation.
 During  labor  or  at  the  time  of  membrane  rupture,  chemo-
prophylaxis  should  be  administered  to  all  pregnant  women
colonized  by  streptococcus.
 Women  with  identified  streptococcus  in  urine  cultures  (at
any  concentration)  during  pregnancy  should  receive  intra-
partum  chemoprophylaxis.
 Women  who  had  a  previous  child  with  streptococcal  infec-
tion  should  receive  chemoprophylaxis.
 If  the  screening  result  is  not  known,  the  patient  should
receive  chemoprophylaxis  in  the  following  cases:  (1)  labor
at  gestational  age  less  than  37  weeks;  (2)  time  of  mem-
brane  rupture  >  18  h;  (3)  presence  of  fever  during  labor
(≥  38 ◦C).
 For  intrapartum  prophylaxis,  the  following  antimicrobialintravenous  units  every  four  hours  until  delivery.  As


















































The  challenges  of  neonatal  sepsis  management  
loading  dose  of  2  g  can  be  used,  and  1  g  intravenous  every
four  hours  until  delivery.
Late neonatal sepsis
Late  neonatal  sepsis  is  that  which  occurs  after  72  h  of  life;
it  is  more  frequent  in  very  low  birth  weight  infants  with
long-term  hospitalization  in  a  neonatal  intensive  care  unit
(ICU)  or  in  late  preterm  or  full-term  infants  requiring  pro-
longed  hospitalization.  The  incidence  of  at  least  one  first
positive  blood  culture  after  72  h  of  life  in  very  low  birth
weight  preterm  infants  (birth  weight  ≤1500  g)  varies  from
20  %  to  35  %,  depending  on  the  assessed  service.5,6,22
The  microorganisms  most  often  associated  with  late
neonatal  sepsis  are  Gram-positive  (79  %),  especially
coagulase-negative  Staphylococcus.  Infections  caused  by
Gram-negative  microorganisms  also  occur,  and  the  incidence
of  fungal  sepsis  has  become  important  in  numerous  centers.
The  occurrence  of  viral  infections,  especially  respiratory
syncytial  virus  and  rhinovirus,  has  been  frequently  reported
in  newborns  with  a  clinical  picture  similar  to  that  of  bacte-
rial  neonatal  sepsis  admitted  to  neonatal  ICUs.23
The  most  important  risk  factors  for  late  neonatal  sepsis
are:
1  Prematurity:  compared  to  full-term  infants,  preterm
infants  have  lower  pro-inflammatory  cytokine  produc-
tion,  lower  natural  killer  (NK)  cell  activation,  decreased
cell-mediated  immunity,  decreased  placental  trans-
fer  of  immunoglobulins,  and  lower  levels  of  serum
complement.24
2  Breach  of  natural  barriers:  lesions  and  lacerations  of  skin
and  mucosa  can  be  a  portal  of  entry  for  bacterial  invasion.
3  Long  term  indwelling  central  catheters  are  portals  of
entry  for  bacteria.
4  Invasive  procedures,  e.g., tracheal  intubation:  the  risk
of  sepsis  increases  with  the  number  of  times  the  new-
born  has  been  intubated;  accidental  extubations  requiring
frequent  reintubation  are  important  causes  of  infection.
5  Use  of  H2  blockers:  gastric  acidity  acts  as  a  barrier  to
bacterial  proliferation  and  invasion;  the  use  of  H2  block-
ers  decreases  the  defense  mechanism  and  increases  the
risk  of  bacterial  invasion.25
6  Prolonged  use  of  empirical  antibiotic  therapy:  the  use
of  empirical  antibiotic  therapy  for  early  neonatal  sep-
sis  for  more  than  five  days  increases  the  incidence  of
late  neonatal  sepsis,  especially  in  units  with  scarce  use
of  breast  milk  and  over-prescription  of  third-generation
cephalosporins.26,27
It  is  important  to  note  that  late  sepsis  also  occurs  in
full-term  newborns,  post-discharge.  A  study  carried  out  in
the  United  States,  analyzing  4255  blood  cultures  collected
from  160,818  full-term  newborns  who  returned  to  the  emer-
gency  department,  aged  between  1  week  and  3  months,
showed  a  positivity  of  0.57  per  1000  newborns,  and  the  most
commonly  found  microorganism  was  Escherichia  coli. The
initial  source  of  infection  in  these  patients  was  a  urinary
tract  infection.28 Screening  for  urinary  tract  infection  in  late






linical  manifestations,  as  well  as  early  neonatal  sepsis,  vary
onsiderably  and  are  nonspecific.  The  clinical  signs  origi-
ate  from  different  systems  and  can  be  grouped  as  follows:
)  apnea,  difficulty  breathing,  cyanosis;  b)  tachycardia  or
radycardia,  poor  perfusion  or  shock;  c)  irritability,  lethargy,
ypotonia,  seizures;  d)  abdominal  distension,  vomiting,  food
ntolerance,  gastric  residue,  hepatomegaly;  e)  unexplained
aundice;  f)  body  temperature  instability;  g)  petechiae  or
urpura.12
In  the  case  of  a  preterm  newborn  hospitalized  for  a  long
eriod  in  the  neonatal  ICU  with  suspected  clinical  signs  of
epsis,  the  collection  of  blood  culture,  CSF,  and  sterile  urine
suprapubic  puncture  or  catheter  sample)  is  recommended
or  cultures.1
Blood  samples  containing  1  mL  of  blood  should  be
ollected  from  two  separate  sites.  The  most  frequently  iden-
ified  microorganism  in  late  neonatal  sepsis  is  coagulase-
egative  Staphylococcus,  and  the  distinction  between
nding  a  contaminating  agent  or  not  is  attained  through
he  positivity  of  blood  cultures  collected  at  two  different
ites.  The  positivity  of  both  blood  cultures  is  indicative  that
oagulase-negative  Staphylococcus  is  the  etiological  agent
f  sepsis.
Complementary  laboratory  tests,  such  as  complete  blood
ount  and  C-reactive  protein,  have  a better  negative  pre-
ictive  value  than  a  positive  predictive  value,  similarly  as
n  early  neonatal  sepsis.  However,  on  certain  occasions,  the
esult  of  the  serum  C-reactive  protein  level  in  combination
ith  the  clinical  picture  helps  to  direct  treatment  decision-
aking.  The  cutoff  point  for  C-reactive  protein  is  10  mg/L.
The  clinical  picture  of  the  newborn  is  crucial  for  the
uspicion  of  neonatal  sepsis  and,  after  the  result  of  blood
ulture,  it  is  the  main  information  to  guide  the  need  for
reatment.  A  newborn  in  good  general  condition  will  only  be
ndicated  for  antibiotic  therapy  if  the  blood  culture  is  posi-
ive,  regardless  of  the  CBC  or  C-reactive  protein  results.  On
he  other  hand,  a  newborn  with  clinical  signs  showing  dis-
ase  will  not  have  indication  for  antibiotic  therapy  only  if
he  blood  culture  is  negative  and  if  they  have  at  least  two
equential  low  C-reactive  protein  levels  24  h  apart.  In  this
ituation,  the  clinician  should  consider  that  the  signs  of  the
isease  are  of  a  non-infectious  bacterial  etiology.
ntibiotic therapy
mpirical  antibiotic  therapy  should  take  into  account  the
ost  likely  etiological  agents  and  their  responses  to  antibi-
tic  therapy.  Although  the  most  common  microorganism
n  late  neonatal  sepsis  is  methicillin-resistant  coagulase-
egative  Staphylococcus,  this  does  not  mean  that  the  initial
mpirical  regimen  should  include  vancomycin.  Several  stud-
es  have  shown  that  not  using  vancomycin  in  the  initial
mpirical  antibiotic  regimen  does  not  increase  mortality,
uration  of  bacteremia,  and  complications  attributed  to  late
eonatal  sepsis.29--32
The  indiscriminate  and  excessive  use  of  vancomycin  is  an
mportant  factor  in  the  emergence  of  multiresistant  flora



























































Krediet  et  al.  studied  66  newborns  with  sepsis  caused
y  coagulase-negative  Staphylococcus  who  received  three
istinct  treatment  regimens:  25  received  cephalothin,
5  received  vancomycin,  and  26  started  the  treatment
ith  cephalothin  and  then  switched  to  vancomycin.
lthough  22  of  the  25  cephalothin-treated  patients  had
ethicillin-resistant  coagulase-negative  Staphylococcus,
he  cephalothin  treatment  was  maintained  and  the  patients
ecovered  without  any  complications  or  recurrence.33
Currently,  there  are  antibiotic  use  management  regimens
or  neonatal  ICUs  that  predict  the  initial  use  of  oxacillin
n  the  initial  empirical  regimen  for  late  neonatal  sepsis
nd  eventual  change  to  vancomycin,  only  when  there  is  no
mprovement  in  the  patient’s  clinical  condition  after  48  h
f  oxacillin  use.29,32 Sepsis  caused  by  coagulase-negative
taphylococcus  usually  has  a  milder  course  and  a  subacute
volution,  which  allows  patients  to  be  observed  for  48  h  on
xacillin  use  and  the  eventual  change  only  if  there  is  no
dequate  response  to  oxacillin  use.
The  empirical  antibiotic  therapy  protocol  for  late  neona-
al  sepsis  in  our  Unit  includes  oxacillin  and  amikacin.
mikacin  is  used  to  cover  Gram-negative  microorganisms
hat  can  occur  in  hospital-acquired  sepsis.  After  microorgan-
sm  identification,  the  antibiotic  therapy  should  be  directed
y  the  antibiogram  test,  except  in  cases  of  oxacillin-
esistant  coagulase-negative  Staphylococcus,  in  which  it  is
aintained  depending  on  the  in  vivo  response  to  oxacillin.
In  case  of  meningitis,  adjustment  of  antibiotic  therapy
ccording  to  the  identified  microorganism  and  antibiogram
est  are  recommended.  If  the  etiological  agent  is  unknown,
hange  of  the  antibiotic  regimen  to  cefepime  is  indicated.
revention of late neonatal sepsis
ome  measures  are  indicated  in  the  prevention  of  late
eonatal  sepsis:
 Handwashing  or  use  of  alcohol  gel:  Handwashing  and/or
use  of  alcohol  gel  is  the  most  effective  measure  to  prevent
infections.  Microorganisms  are  carried  by  the  hands  when
handling  a  patient.  The  five  moments  of  hand  hygiene  rec-
ommended  by  the  World  Health  Organization  should  be
emphasized:  1.  before  contact  with  the  patient;  2.  before
the  procedure  is  performed;  3.  after  risk  of  exposure  to
biological  fluids;  4.  after  contact  with  the  patient;  5.  after
contact  with  areas  near  the  patient.
 Appropriate  and  well-defined  care  bundles,  with  central
intravascular  catheters  and  endotracheal  tubes  that  are
closely  followed  to  reduce  contamination.34
 Trophic  enteral  feeding:  early  onset  of  trophic  feed-
ing  stimulates  the  gastrointestinal  tract,  stimulating
intestinal  maturity,  preventing  villous  atrophy,  and  also
decreasing  bacterial  translocation  and  invasion  through
the  intestinal  mucosa.35
 Use  of  breast  milk:  breast  milk  contains  significant  con-
centrations  of  IgA  and  oligosaccharides  that  give  it
anti-infectious  properties.  The  exclusive  use  of  breast
milk  results  in  more  diverse  intestinal  microbiota,  which
leads  to  a  lower  probability  of  infections.36,37
 Probiotics:  although  there  are  meta-analyses  showing  that
probiotics  may  be  useful  in  preventing  late  neonatal  sep-Procianoy  RS,  Silveira  RC
sis,  there  are  still  many  questions  regarding  their  routine
use.  The  studies  were  performed  with  different  types  of
probiotics,  different  dosages,  and  highly  variable  treat-
ment  times,  which  makes  the  generalization  of  results
very  difficult.38,39
 Lactoferrin:  there  are  conflicting  studies  regarding  the
role  of  lactoferrin  as  a  protective  factor  against  late
neonatal  sepsis.  An  Italian  collaborative  randomized  trial
included  472  very  low  birth  weight  infants:  the  lactofer-
rin  group  with  153  patients,  the  lactoferrin  and  probiotic
group  with  151  patients,  and  the  placebo  group  (glucose
5  %)  with  168  patients,  treated  from  birth  to  30  days  of
life.Late  sepsis  was  significantly  lower  in  the  groups  that
received  lactoferrin.40 However,  a recently  published  col-
laborative  randomized  clinical  trial  was  carried  out  in
the  United  Kingdom  with  2203  newborns,  of  gestational
age  <32  weeks:  1099  in  the  lactoferrin  group  up  to  34
weeks  of  corrected  gestational  age  and  1104  in  the  con-
trol  group  receiving  sucrose  up  to  34  weeks  of  corrected
age.  There  was  no  significant  difference  in  the  incidence
of  late  sepsis.41 At  this  time,  the  indication  of  lactoferrin
as  a  preventive  measure  for  late  neonatal  sepsis  is  still
under  evaluation.
onclusions
anagement  of  neonatal  sepsis  is  always  a  challenge.  Neona-
al  sepsis  is  a  frequent  cause  of  neonatal  morbidity  and
ortality,  especially  in  developing  countries.  Its  diagnosis
s  difficult,  since  clinical  signs  are  nonspecific  and  comple-
entary  exams  have  low  accuracy.  Continuous  observation
f  the  patient,  knowing  how  to  take  into  account  clinical
igns,  and  observing  risk  factors  are  essential  for  diagnos-
ic  suspicion.  When  neonatal  sepsis  is  suspected,  always
ollect  samples  for  bacteriological  analysis  before  starting
he  empirical  treatment.  The  decision  to  start  empirical
ntibiotic  therapy  and  the  choice  of  the  most  appropriate
reatment  regimen  are  crucial.  Avoiding  routine  vancomycin
se  in  the  empirical  antibiotic  regimen  in  late  neonatal  sep-
is  is  important  to  prevent  bacterial  resistance  and  invasive
ungal  infections.  The  main  protective  mechanisms  against
eonatal  sepsis  are  handwashing  and  the  use  of  breast  milk.
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